Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Randomized, Multiple Dose, Placebo And Active Controlled 4-Way Crossover Study To Investigate The Effects Of Inhaled PF-00610355 On QT/QTC Interval In Healthy Subjects.

Next Previous
Trial Profile

A Double Blind, Randomized, Multiple Dose, Placebo And Active Controlled 4-Way Crossover Study To Investigate The Effects Of Inhaled PF-00610355 On QT/QTC Interval In Healthy Subjects.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 610355 (Primary) ; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Asthma; Chronic obstructive pulmonary disease; Community-acquired pneumonia; Intra-abdominal infections; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Pharmacodynamics

Most Recent Events

  • 11 Jan 2011 Actual initiation date changed from 1 May 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
  • 28 Jul 2010 Additional trial location [Belgium] identified as reported by ClinicalTrials.gov.
  • 28 Jul 2010 Actual initiation date (May 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top